Charles Explorer logo
🇨🇿

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors

Publikace na 1. lékařská fakulta |
2020

Tento text není v aktuálním jazyce dostupný. Zobrazuje se verze "en".Abstrakt

Accessible prognostic tools are needed to individualize treatment of neuroendocrine tumors (NETs). Data suggest neutrophil/lymphocyte ratios (NLRs) have prognostic value in some solid tumors, including NETs.

In the randomized double-blind CLARINET study (NCT00353496; EudraCT 2005-004904-35), the somatostatin analog lanreotide autogel/depot increased progression-free survival (PFS) compared with placebo in patients with inoperable or metastatic intestinal and pancreatic NETs (grades 1-2, Ki-67 4; n = 25)]. Furthermore, NLRs were not prognostic in Cox models, irrespective of subgroups used.

The therapeutic effect of lanreotide autogel/depot 120 mg was independent of NLRs (P > 0.1). These exploratory post-hoc analyses in patients with advanced intestinal and pancreatic NETs contrast with previous data suggesting NLR has prognostic potential in NETs.

This may reflect the inclusion of patients with lower-grade tumors or use of higher NLR cutoff values in the current analysis.